braintumors
Conditions
Interventions
Sponsors
Academisch Medisch Centrum
Eligibility
Age
2 Years to 17 Years
Inclusion criteria
Inclusion criteria: - Radiologicaland if possible histological proven diagnosis of any CNS tumor (M0-M4) - Any age group - Written informed consent obtained of the patients and/or their parents or legal guardians
Exclusion criteria
Exclusion criteria: see inclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Development of techniques for detection of MRD (PCR: RNA-DNA, next generation sequencing) from any CNS tumor in CSF, PB and urine based on tumor derived expression profiles for candidate genes or DNA aberrations . 2. Compare efficacy of different methods of MRD detection in different body fluids in patients with a CNS tumor. 3. Does MRD at diagnosis and its kinetics during therapy relate with any of the biological subtypes of tumor groups? 4. Does MRD at diagnosis and its kinetics during therapy correlate with treatment outcome? The endpoint of this study is to determine the presence and, if present, the quantification of MRD in body fluids of patients with a CNS tumor at diagnosis, during treatment and follow-up using different techniques (RQ-PCR, digital PCR and Next generation sequencing of tumor derived abberations) and correlate this with staging and outcome. | — |
Countries
The Netherlands
Outcome results
None listed